Clinical Trial Update: Amlexanox for Type 2 Diabetes and Obesity [Phase 2]

View source ↗

Summary

Phase 2 trial of amlexanox for type 2 diabetes mellitus and obesity was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Amlexanox (amlexanox)

Snippet

Sponsor: University of Michigan | Conditions: Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-01-17